9 Eli Lilly Insiders Execute $437,850 in Stock Transactions Within 7 Days

Nine Eli Lilly (LLY) insiders executed 13 stock transactions totaling $437,850 between February 16 and February 23, 2026, according to recent SEC filings. The activity primarily consisted of stock awards to executives and tax-related share dispositions, with no direct market purchases or sales reported.

The Trades

The bulk of the insider activity occurred on February 9, when six executives received stock awards totaling 70,408 shares valued at $73.6 million based on the award price of $1,044.67 per share. CEO David Ricks led the group with an award of 38,914 shares worth $40.7 million, representing more than half of the total value awarded.

Following the awards, four executives exercised options and made tax payments between February 16-19. These tax-related transactions accounted for $437,850 in disposed shares at $1,040 per share. The executives who paid taxes on vested shares included EVP & CFO Lucas Montarce ($166,122), EVP Adrienne Brown ($176,765), and EVP Kenneth Custer ($94,963).

Notably, five board members received zero-share awards on February 17 at $1,036.05, likely representing deferred compensation or phantom stock units that don't involve actual share transfers. EVP Eric Dozier also gifted 481 shares on February 19, a transaction typically done for estate planning or charitable purposes.

Who's Trading

The insider group spans Lilly's entire C-suite and several board members. CEO David Ricks received the largest award at $40.7 million, followed by EVP Daniel Skovronsky with $16.2 million in awards. The executive team receiving awards manages critical divisions including oncology, immunology, and the company's research laboratories.

CFO Lucas Montarce's participation is particularly noteworthy, as he received both a $1.4 million award and subsequently paid $166,122 in taxes on vested shares. This dual activity suggests confidence in the company's financial position while meeting tax obligations.

Board members including Ralph Alvarez, J Erik Fyrwald, and Juan Luciano received the zero-share awards, indicating ongoing board compensation adjustments. These directors bring diverse experience from companies across pharmaceuticals, agriculture, and consumer goods sectors.

What to Watch

The timing of these transactions carries significance as Lilly's stock trades near all-time highs above $1,000 per share, driven by strong demand for its diabetes and obesity drugs Mounjaro and Zepbound. The February 9 awards at $1,044.67 represent annual equity compensation grants that typically vest over multiple years, aligning executive interests with long-term shareholder value.

The absence of any open market sales is notable. Despite the stock's strong performance—up significantly over the past year—no insider chose to liquidate holdings beyond required tax payments. The tax withholding transactions at $1,040 per share were mandatory dispositions to cover tax obligations on vesting restricted stock, not discretionary sales.

The $73.6 million in total awards reflects Lilly's robust compensation practices amid record revenues and profits. The company's market capitalization exceeds $700 billion, making it one of the most valuable pharmaceutical companies globally. These equity grants, while substantial, represent a tiny fraction of the company's overall value.

For context, Lilly reported fourth-quarter 2025 revenue of $13.4 billion, beating analyst estimates by over $1 billion. The company's GLP-1 drugs continue to see unprecedented demand, with manufacturing capacity expansions underway to meet global needs. The insider awards align with this period of exceptional business performance.

Investors should note that large equity awards are standard practice for pharmaceutical executives, particularly when company performance exceeds targets. The clustering of transactions in February aligns with typical annual grant cycles rather than indicating coordinated trading activity. The mix of awards, exercises, and tax payments represents routine compensation events rather than market-timing decisions.